

# Diagnostic Criteria Checklist

Opioid use disorder (OUD) is a problematic pattern of opioid use leading to clinically significant impairment or distress, as manifested by **at least two of the following symptoms, occurring within a 12-month period:**

- 1** Opioids are often taken in larger amounts or over a longer period than was intended.
- 2** There is a persistent desire or unsuccessful efforts to cut down on or control opioid use.
- 3** A great deal of time is spent in activities necessary to obtain opioids, use opioids, or recover from their effects.
- 4** Craving, or a strong desire or urge to use opioids.
- 5** Recurrent opioid use resulting in a failure to fulfill role obligations at work, school, or home.
- 6** Continued opioid use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of opioids.
- 7** Important social, occupational, or recreational activities are given up or reduced because of opioid use.
- 8** Recurrent opioid use in situations in which it is physically hazardous.
- 9** Continued opioid use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the opioid.
- 10** Tolerance, as defined by either of the following:
  - a. a need for markedly increased amounts of opioids to achieve intoxication or desired effect
  - b. a markedly diminished effect with continued use of the same amount of an opioid.
- 11** Withdrawal, as manifested by either of the following:
  - a. the characteristic opioid withdrawal syndrome
  - b. opioids or a related substance are taken to relieve or avoid withdrawal symptoms.

## Specify whether the client is

### → in early remission:

After the full criteria for OUD were previously met, none of the criteria for OUD have been met for at least three months but for less than 12 months (with the exception that Criterion 4, “Craving, or a strong desire or urge to use opioids,” may be met).

### → in sustained remission:

After the full criteria for OUD were previously met, none of the criteria for OUD have been met at any time during a period of 12 months or longer (with the exception that Criterion 4, “Craving, or a strong desire or urge to use opioids,” may be met).

### → on maintenance therapy:

This additional specifier is used if the individual is taking a prescribed agonist medication, such as methadone or buprenorphine, and none of the criteria for OUD have been met for that class of medication (except tolerance to, or withdrawal from, the agonist). This category also applies to those individuals being maintained on a partial agonist, an agonist/antagonist, or a full antagonist, such as oral naltrexone or depot naltrexone.

### → in a controlled environment:

This additional specifier is used if the individual is in an environment where access to opioids is restricted.

### Code based on current severity:

Note for *International Classification of Diseases*, 10th revision, Clinical Modification (ICD-10-CM) codes: If an opioid intoxication, an opioid withdrawal, or another opioid-induced mental disorder is also present, do not use the codes below for OUD. Instead, the comorbid OUD is indicated in the fourth character of the opioid-induced disorder code (see the coding note for opioid intoxication, opioid withdrawal, or specific opioid-induced mental disorder). For example, if there is comorbid opioid-induced depressive disorder and OUD, only the opioid-induced depressive disorder code is given, with the fourth character indicating whether the comorbid OUD is mild, moderate, or severe: F11.14 for mild OUD with opioid-induced depressive disorder or F11.24 for moderate or severe OUD with opioid-induced depressive disorder.

*Specify current severity:*

- **305.50 (F11.10) Mild:** Presence of 2–3 symptoms
- **304.00 (F11.20) Moderate:** Presence of 4–5 symptoms
- **304.00 (F11.20) Severe:** Presence of 6 or more symptoms.

SOURCE: Adapted from American Psychiatric Association, *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*, Washington, D.C., October 1, 2020.

